Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma

Published:2013-09-12 Issue:2 Volume:140 Page:259-272
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Cycon Kelly A.¹,Mulvaney Kathleen²,Rimsza Lisa M.³,Persky Daniel⁴,Murphy Shawn P.⁵

Affiliation:

1. Zeptometrix Corp.; Buffalo; NY; USA

2. University of North Carolina; Chapel Hill; NC; USA

3. Department of Pathology; University of Arizona; Tucson; AZ; USA

4. Yale University Cancer Center; New Haven; CT; USA

5. Departments of Obstetrics and Gynecology/Microbiology and Immunology; University of Rochester; Rochester; NY; USA

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imm.12136/fullpdf

Reference72 articles.

1. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen;Rimsza;Leuk Lymphoma,2007

2. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project;Rimsza;Blood,2004

3. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma;Rosenwald;N Engl J Med,2002

4. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy;Veelken;Ann Oncol,2007

5. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma;Wilkinson;Blood,2012

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classical Monocytes Shuttling for Precise Delivery of Nanotherapeutics to Glioblastoma;Advanced Healthcare Materials;2024-08-30

2. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies;Cancer Communications;2024-07-28

3. Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer;Nature Communications;2024-07-18

4. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator;Medical Oncology;2024-03-05

5. Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence;Nature Reviews Urology;2024-02-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3